Insulin NPH

1
Insulin NPH
Brands

DEA Class; OTC

Common Brand Names; Humulin N, Novolin N

  • Antidiabetics, Insulins; 
  • Antidiabetics, Intermediate-Acting Insulins

Intermediate-acting insulin with a longer onset and duration of activity when compared to regular insulin
Used in adult and pediatric patients with type 1 and type 2 diabetes mellitus
Usually requires 2 or more injections/day when used as a basal insulin along with rapid-acting prandial insulins

Indicated for the treatment of type 1 diabetes mellitus.

For the treatment of type 2 diabetes mellitus.
For the treatment of gestational diabetes or for the treatment of patients with pre-existing diabetes mellitus (type 1 or type 2) who are now pregnant.

Hypoglycemia

Documented hypersensitivity reactions to product or excipients

Hypoglycemia

Lipodystrophy

Lipohypertrophy

Local allergic reaction

Hypokalemia

Muscle weakness

Paresthesia

Tremor

Edema

Pain

Itching

Nausea

Hunger

Numbness of mouth

Localized cutaneous amyloidosis

Never share pen between patients even if needle is changed

Intermediate-acting insulin; do not use for circumstances that require rapid-acting insulin

Caution with decreased insulin requirements: Diarrhea, nausea/vomiting, malabsorption, hypothyroidism, renal impairment, hepatic impairment

Hypokalemia may occur

Not for IV or IM administration

Use with caution in renal and hepatic impairment (dosage requirements may be reduced)

Caution with increased insulin requirements: Fever, hyperthyroidism, trauma, infection, surgery

Thiazolidinediones are peroxisome proliferator-activated receptor (PPAR)-gamma agonists and can cause dose-related fluid retention, particularly when used in combination with insulin; fluid retention may lead to or exacerbate heart failure; monitor for signs and symptoms of heart failure, treat accordingly, and consider discontinuing thiazolidinediones

When hyper-or hypoglycemia occurs, carry out changes in insulin regimen under close medical supervision; increase frequency of blood glucose monitoring

Accidental mix-ups between insulin products reported; to avoid medication errors between this and other insulins, instruct patients to always check insulin label before each injection

Available data from published studies over decades have not established association with human insulin use during pregnancy and major birth defects, miscarriage or adverse maternal or fetal Outcomes

Available data from published literature suggests that exogenous human insulin products, are transferred into human milk

Specific maximum dosage information is not available. Individualize dosage based on careful monitoring of blood glucose and other clinical parameters in all patient populations.

NPH, human insulin isophane rDNA origin

injectable suspension

  • 100units/mL (3mL)
  • 100units/mL (10mL)
DrugsAce
Logo